Zenas BioPharma (ZBIO) Cash from Investing Activities (2024 - 2026)

Zenas BioPharma's Cash from Investing Activities history runs 3 years deep, the most recent figure standing at $31.6 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 136.64% year-over-year to $31.6 million in Q1 2026; TTM through Mar 2026 was -$134.0 million, a 14.72% decrease from a year earlier, with the FY2025 full-year figure at -$251.9 million, down 724.45% from the prior year.
• Cash from Investing Activities advanced to $31.6 million in Q1 2026 per ZBIO's latest filing, from -$93.4 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $40.0 million in Q3 2025 and bottomed at -$112.3 million in Q2 2025.
• The 3-year median for Cash from Investing Activities is -$3.7 million (2024), against an average of -$27.9 million.
• Biggest YoY gain for Cash from Investing Activities was 249.64% in 2025; the steepest drop was 392054.55% in 2025.
• Year by year, Cash from Investing Activities stood at -$3.7 million in 2024, then plunged by 2399.71% to -$93.4 million in 2025, then surged by 133.86% to $31.6 million in 2026.
• Per Business Quant, the three latest ZBIO Cash from Investing Activities figures stand at $31.6 million (Q1 2026), -$93.4 million (Q4 2025), and $40.0 million (Q3 2025).